 The FDA has granted Orphan Drug Designation to Marker Therapeutics Incs NASDAQ: MRKR MT-601, a multi-tumor-associated antigen MultiTAA-specific T cell product for pancreatic cancer. Following MT-401 for post-transplant acute myeloid leukemia AML, MT-601 is Markers second novel MultiTAA-specific T cell product to receive orphan drug designation and the first in a solid tumor indication. 